Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
    • Access insights
    • Health Equity through Her Lens
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Jayasree K. Iyer joins panel discussion on AMR in London

On 26 April, Jayasree K. Iyer will join a panel, chaired by Jim O’Neill, to explore the rise of superbugs and the role of governments, NGOs, public and private sectors in tackling this growing threat. The event is organised to celebrate the publication of “Superbugs: An arms race against bacteria” by William Hall, Anthony McDonnell and Jim O’Neill. Jayasree will speak on the key findings of the Foundation’s Antimicrobial Resistance Benchmark and how it incentivises pharmaceutical companies to play their part and curb AMR.

Date

26 April 2018

Jayasree will speak on the key findings of the Foundation’s Antimicrobial Resistance Benchmark and how it incentivises pharmaceutical companies to play their part and curb AMR.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved